Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：1

作者：

Schuler, M. ^{[1
]}

Yang, J. ^{[2
,3
]}

Sequist, L. V. ^{[4
,5
]}

Yamamoto, N. ^{[6
]}

Zhou, C. ^{[7
]}

O'Byrne, K. ^{[8
,9
]}

Hirsh, V. ^{[10
]}

Mok, T. ^{[11
]}

Shah, R. ^{[12
]}

Wu, Y. -L. ^{[13
,14
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[3] Natl Taiwan Univ, Taipei, Taiwan

[4] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA

[5] Harvard Med Sch, Boston, MA USA

[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China

[8] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia

[9] Queensland Univ Technol, Brisbane, Qld, Australia

[10] McGill Univ, Dept Oncol, Montreal, PQ, Canada

[11] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China

[12] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England

[13] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China

[14] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

来源：

关键词：

D O I：

10.1016/S1556-0864(16)30248-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

138PD

引用

页码：S116 / S117

页数：2